文献速递真菌感染医院感染防控

艾沙康唑在高危血液肿瘤及造血干细胞移植患者中一级预防的突破性真菌感染回顾性分析

Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
PubMed 文献 · Clin Infect Dis · 2020-01-01

在初诊或复发/难治急性髓系白血病患者中,bIFI分别复杂化了10.2%的ISA、4.1%的泊沙康唑和1.1%的伏立康唑疗程,侵袭性肺曲霉病分别占6.8%、1.3%和0%。

要点

  • 艾沙康唑一级预防期间bIFI发生率为6.1%疗程,全部见于中性粒细胞减少期。
  • bIFI后42天死亡率为58.3%,以曲霉和毛霉为主。
  • 急性髓系白血病患者中艾沙康唑组bIFI和侵袭性肺曲霉病发生率高于泊沙康唑和伏立康唑组。

核心结论

  • 艾沙康唑一级预防期间观察到突破性侵袭性真菌感染率升高,尤其是侵袭性肺曲霉病,需进一步研究确定其一级预防地位。

主要发现

  • bIFI病原包括烟曲霉5例、曲霉属2例、毛霉目2例、镰刀菌属2例、光滑念珠菌1例。
  • 7例(58.3%)在bIFI发生后42天内死亡。
  • 初诊或复发/难治急性髓系白血病患者中,bIFI分别复杂化10.2%的艾沙康唑、4.1%的泊沙康唑和1.1%的伏立康唑疗程。
  • 侵袭性肺曲霉病分别复杂化6.8%的艾沙康唑、1.3%的泊沙康唑和0%的伏立康唑疗程。

临床怎么用

  • 在高危血液肿瘤及造血干细胞移植患者中,艾沙康唑一级预防期间需警惕突破性侵袭性真菌感染,尤其是侵袭性肺曲霉病。
  • 中性粒细胞减少期是bIFI发生的关键窗口,应加强监测。

局限性

  • 回顾性研究设计。
  • 单中心?原文未明确说明,但为回顾性综述。
  • 非随机对照,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isavuconazole (ISA) is an attractive candidate for primary mold-active prophylaxis in high-risk patients with hematologic malignancies or hematopoietic cell transplant (HCT) recipients. However, data supporting the use of ISA for primary prophylaxis in these patients are lacking. METHODS: We conducted a retrospective review of breakthrough invasive fungal infections (bIFIs) among adult hematologic malignancy patients and HCT recipients who received ≥7 days of ISA primary prophylaxis between 1 September 2016 and 30 September 2018. The incidence of bIFIs in patients receiving ISA was compared to those receiving posaconazole (POS) and voriconazole (VOR) during the same time period. RESULTS: One hundred forty-five patients received 197 courses of ISA prophylaxis. Twelve bIFIs (Aspergillus fumigatus [5], Aspergillus species [2], Mucorales [2], Fusarium species [2], and Candida glabrata [1]) occurred, representing 8.3% of patients and 6.1% of courses, after a median duration of 14 days of ISA prophylaxis. All bIFIs occurred during periods of neutropenia. Seven patients (58.3%) died within 42 days of onset of bIFI. In addition, bIFIs complicated 10.2% of ISA, 4.1% of POS, and 1.1% of VOR courses among patients with de novo or relapsed/refractory acute myeloid leukemia during the study period, with invasive pulmonary aspergillosis (IPA) complicating 6.8% of ISA, 1.3% of POS, and zero VOR courses. CONCLUSIONS: Although ISA has been approved for treatment of invasive Aspergillus and mucormycosis, we observed an increased rate of bIFI, notably IPA, using ISA for primary prophylaxis. These results support the need for further study to determine the role of ISA as primary prophylaxis.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020. PMID: 30958538. doi:10.1093/cid/ciz282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。